Global Multiple Myeloma Drug Market Sales Revenue Clinical Trials Pipeline Report 2015

Multiple myeloma incidences are increasing across the globe and presently available therapeutics are unable to offer effective clinical benefits. Multiple myeloma chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required. Surgery and radiation are equally ineffective and they are not viable for most of the cases. Pharmaceutical companies have identified this scenario due to which they are investing more funds in research and development segment. As a result, investigators would be able to screen more lead molecules for their safety and efficacy in multiple myeloma. Innovative modalities are being studied in clinical trial and they are expected to yield significant results thereby surpassing the issues related with presently available modalities in coming years.

Download Report:

https://www.kuickresearch.com/report-Global-Multiple-Myeloma-Drug-Market-&-Pipeline-Insight-2015.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Multiple Myeloma Drug Market & Pipeline Insight 2015" Table of Contents

1. Introduction to Multiple Myeloma

2. Mechanism of Multiple Myeloma Drug

3. Global Multiple Myeloma Drug Market Analysis
3.1 Current Market Scenario
3.2 Multiple Myeloma Drug Clinical Pipeline Overview

4. Global Multiple Myeloma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. Global Multiple Myeloma Drug Market Future Prospects

6. Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase
6.1 Research
6.2 Preclinical
6.3 Clinical
6.4 Phase-I
6.5 Phase-I/II
6.6 Phase-II
6.7 Phase-III
6.8 Preregistration

7. Marketed Multiple Myeloma Drugs Clinical Insight
7.1 Bendamustine (Innomustine® Levact®, Treanda® & Treakisym®)
7.2 Bortezomib (Velcade®)
7.3 Carfilzomib (Kyprolis®)
7.4 Doxorubicin Liposomal - ALZA
7.5 Interferon Alpha-2b (Intron® A)
7.6 Lenalidomide (Ladevina® & Revlimid®)
7.7 Pomalidomide (Imnovid® & Pomalyst®)
7.8 Thalidomide (Thaled®, Thalidomide Celgene™ & Thalomid®)
7.9 Zoledronic Acid (Zometa®)

8. Discontinued & Suspended Multiple Myeloma Drugs in Clinical Pipeline
8.1 No Development Reported
8.2 Discontinued
8.3 Suspended

9. Competitive Landscape
9.1 AbbVie
9.2 Altor BioScience
9.3 Astellas Pharma
9.4 Astex Pharmaceuticals
9.5 Benovus Bio
9.6 Biogen Idec
9.7 Bristol-Myers Squibb
9.8 Celegen Pharmaceuticals
9.9 Cleave Biosciences
9.10 Genmab
9.11 Novartis
9.12 Onyx Pharmaceuticals
9.13 Pfizer
9.14 Millennium Pharmaceuticals
9.15 Vaxil Biotherapeutics

Figure 1-1: Type of Blood Cancer
Figure 1-2: Development of Multiple Myeloma in Body
Figure 1-3: Causes of Multiple Myeloma
Figure 1-4: Symptoms of Multiple Myeloma
Figure 2-1: Diagnosis of Multiple Myeloma
Figure 2-2: Stages of Multiple Myeloma
Figure 2-3: Treatments Available for Multiple Myeloma
Figure 2-4: Mechanism of Doxorubicin
Figure 2-5: Mechanism of MAGE-A3 Vaccine
Figure 2-6: Mechanism of Carfilzomib
Figure 3-1: Global Multiple Myeloma Drug Market Size (US$ Billion), 2015-2019
Figure 3-2: Multiple Myeloma Drug Pipeline by Phase (%), 2015
Figure 3-3: Multiple Myeloma Drug Pipeline by Phase (Number), 2015
Figure 3-4: No Development Reported in Multiple Myeloma Drug Pipeline by Phase (%), 2015
Figure 3-5: No Development Reported in Multiple Myeloma Drug Pipeline by Phase (Number), 2015
Figure 3-6: Discontinued Multiple Myeloma Drug Pipeline by Phase (%), 2015
Figure 3-7: Discontinued Multiple Myeloma Drug Pipeline by Phase (Number), 2015
Figure 3-8: Suspended Multiple Myeloma Drug Pipeline by Phase (%), 2015
Figure 3-9: Suspended Multiple Myeloma Drug Pipeline by Phase (Number), 2015
Figure 4-1: Global Multiple Myeloma Drug Market Favorable Parameters
Figure 4-2: Global Multiple Myeloma Drug Commercialization Challenges
Figure 9-1: Altor BioScience Clincal Pipeline
Figure 9-2: Astex Pharmaceuticals Clincal Pipeline
Figure 9-3: Benovus Bio Clincal Pipeline
Figure 9-4: Genmab Clincal Pipeline
Figure 9-5: Onyx Pharmaceuticals Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.